Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

eye diseases such as retinal detachment, diabetic vitreous hemorrhage and macular hole. It is estimated that 600,000 vitrectomies are carried out annually worldwide.

Vitrectomy is used to induce a posterior vitreous detachment (PVD), which involves removing the vitreous from the eye. As microplasmin is a proteolytic enzyme, it is able to cleave the molecular structures which link the vitreous to the retina, meaning that it could facilitate, and in some cases even avoid, vitrectomy and therefore induce PVD without the risks inherent in the current surgical procedure.

The MIVI III trial, which has recruited a total of 125 patients, is designed to assess the safety and efficacy of administering microplasmin intravitreal injection 7 days prior to vitrectomy.

- ThromboGenics completed patient enrolment for its Phase II MITI IV trial

Microplasmin is also being studied for the treatment of acute ischemic stroke. In this indication, the fact that it is a direct-acting thrombolytic agent (breaks down blood clots) and is independent of plasminogen means that it could restore blood flow efficiently for a longer period after the stroke event, and with potentially fewer side-effects than other thrombolytic agents. The MITI IV study is placebo controlled and is evaluating the safety and preliminary efficacy of microplasmin in three different doses when administered intravenously to acute stroke patients between four and twelve hours after the onset of the stroke. This trial has recruited a total of 40 patients.

- In January, ThromboGenics announced that its novel anti-cancer antibody TB-403 had begun its initial Phase I clinical trial in Denmark.

TB-403 (Anti-PIGF) is a potential breakthrough in the treatment of cancer. It is a humanized monoclonal antibody that blocks the formation of the new blood vessels that are needed by solid tumours to support their growth. TB-403 therefore has the potential to minimise the growth and spread of ca
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Peter Walter ... Biomedical Science for his pioneering work on how proteins ... components of a regulatory mechanism that cells use to ... Dr. Walter is a professor of biochemistry at the ... groundwork for treating a range of human diseases related ...
(Date:3/26/2015)... March 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... on providing advanced testing solutions for the detection ... for the three months and full year ended ... Financial Results:Revenue for the quarter ended December 31, ... the fourth quarter of 2013 and $1.5 million ...
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will ... Align Technology, on “ Conducting Postmarket Registries - Rationale ... Conference and Exhibition on April 25th through April 28th ... poster presentation, Ale Gicqueau and Victor Chen will discuss ... the requirements and resources to conduct the registry, as ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3
... Advanced Scientific Knowledge, Highlight Most Recent ... ... ArcMesa Educators, an accredited,provider of continuing education courses, is proud ... by years of scientific,experience and advanced degrees in molecular biology, structural ...
... AUSTIN, Texas, Sept. 27 Luminex Corporation,(Nasdaq: ... at the,Biotechnology Industry Organization Investor Forum to be ... investor presentation by Patrick J. Balthrop, president and ... officer, will,begin at 9:30 a.m. Pacific time; 12:30 ...
... GENZ ) confirmed today that it will not change ... $5.60 in cash per,outstanding common share as set forth ... owns approximately 22 percent of the,outstanding shares of Bioenvision ... its preferred stock that carry a unique set of,rights ...
Cached Biology Technology:ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 2ArcMesa Educators Appoints Medical Advisor and Directors to CME Development Team 3Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 2Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share 3
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
(Date:3/17/2015)... March 17, 2015  MecklerMedia Corporation (OTCQX: MECK) ... for service robots ever held in ... on May 11-13, 2015 at the Javits Convention ... the event include: Acorn Product Development; Axis NJ; ... Kinova Robotics; Littler; NewBotic Corporation; Neya Systems LLC; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... is a severely debilitating psychiatric disease that is thought ... nervous system; however, major breakthroughs linking its genetics to ... PhD assistant professor of Pediatrics at Northwestern University,s Feinberg ... Molecular Genetics Program of Children,s Memorial Research Center studies ...
... A common variation of the gene involved in ... linked to problem behaviors in adults with developmental and ... published in the July 2009 issue of the ... are available online at http://tinyurl.com/mw8baj . "Problem ...
... only a few millimeters up to a few centimeters in ... research, because they possess the extraordinary ability to regenerate lost ... even grow an entirely new worm out of minute amputated ... Berlin, Germany together with researchers in the US and Canada ...
Cached Biology News:A genetic basis for schizophrenia 2Genetic marker linked to problem behaviors in adults with developmental disabilities 2International research team seeks to unravel flatworm regeneration 2
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
... Rabbit polyclonal to HDAC4 - ChIP ... the class II mammalian histone deacetylases, which ... C-terminal sequence is highly similar to the ... other deacetylases, shuttles between the nucleus and ...
Biology Products: